About this trial
Assess quality of life of patients using prolonged oxygen therapy
Eligibility criteria
Qualifiers
Patients with a clinical, radiological and/or anatomopathological diagnosis of COPD and ILD according to the 2020 ATS/JRS/ALAT guidelines;
Age over 18 years;
Clinical stability (absence of exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;
Patients who are on optimized drug therapy, including long-term home oxygen therapy (LTOT)
Disqualifiers
Presence of other concomitant lung diseases;
Myocardial infarction within four months prior to the start of the study, unstable angina or severe heart disease (NYHA functional class III-IV) and/or decompensated.
Patients who received a lung transplant during the study
Living outside the coverage area or moving out of state
Trial design
Treatments tested in this trial
- Group Monitoring
- Control Group
Treatment groups
Sponsors and collaborators
University of Sao Paulo General Hospital
Lead sponsor
Air Liquide SA
Collaborator